# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Tessa Romero maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Overweight and lowers the price targe...
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240238387
Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $28 price ...
HC Wainwright & Co. analyst Yi Chen reiterates EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $30 price...